Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-579-8 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No studies are available. Based on molecular structure, molecular weight, water solubility and octanol-water partition coefficient, it can be expected taht both oral and dermal absorption rates are moderate, distribution in the body is wide and that elimination occurs mainly by metabolism. The nephrotoxicity observed in the 90-day toxicity study confirm that the substance has at least moderate oral absorption rate.
Key value for chemical safety assessment
Additional information
There is no reliable and relevant information source in which the toxicokinetic properties (absorption, distribution, metabolism, elimination) of the submission substance were investigated. The expected toxicokinetic behaviour is derived from the physicochemical properties and the results from the available toxicological data following the guide given in the REACH guidance document R.7c.
CHIMEXANE HB is a substance composed of constituents having a molecular weight in the 379-519 g/mol range. It is a pasty solid with an estimated water solubility above 158.4 mg/L at 20°C. Vapour pressure was determined to be 0.0085 Pa at 20°C and it has lipophilic properties (3<log Kow<4.5 for the main constituents, extrapolated log Kow= 4 for the submission substance). The surface tension is 30.08 mN/m at 20°C at 1000 mg/L. More details regarding these data can be found in the section 4 of CHIMEXANE HB IUCLID dossier.
Absorption:
In an acute oral toxicity study, the major clinical signs observed in animals dosed 2000 mg/kg bw were hypoactivity, piloerection and dyspnea. Lower body weight gain was observed in the surviving animal dosed 2000 mg/kg bw and in 1/5 females dosed 300 mg/kg bw. The systemic toxicity effects observed at 2000 mg/kg bw indicate that thesubmission substance is absorbed when administered orally at high doses.
In an acute dermal toxicity study, no systemic effects were observed at 2000 mg/kg bw CHIMEXANE HB. However, the submission substance has a molecular weight < 500 and is a lipophilic substance (log Kow = 4) and has moderate water solubility: dermal absorption is therefore expected. Also, as the substance has also corrosive properties, damage to the skin surface may enhance penetration.
In a 90-day repeated dose toxicity study, tubular necrosis with clinical chemistry changes were observed in animals dosed 450 mg/kg bw/day CHIMEXANE HB. These effects indicate that the submission substance is absorbed when administered orally at moderately high doses.
Thus, indications of oral and dermal uptake of CHIMEXANE HB/the submission are given. Therefore the bioavailability of CHIMEXANE HB/the submission substance can be considered to be existent but maybe limited.
Distribution:
Available physico-chemical data (low molecular weight, lipophilicity and moderate water solubility) indicate that the submission substance could be distributed to many tissues and, due to its lipophilicity, may have a particular affinity for fatty tissues.
Metabolism:
No data are available but differences in cytotoxicity were observed with and without the use of a metabolic activation system in differentin vitrogenotoxicity studies (HPRT,chromosome aberration assay). This indicates that the submission substance may be metabolised by hepatic microsomal fractions.
Excretion:
As nephrotoxicity was observed in the 90-day repeated dose toxicity study, it can be considered that the submission substance and its metabolites are excreted in urine.
Accumulative potential:
Based on some toxicological studies that provide indications on CHIMEXANE HB absorption and metabolism (repeated dose toxicity study and genotoxicity studies) and on physico-chemical information (molecular weights < 500 and log Kow =4), it is concluded that CHIMEXANE HB is partially bioavailable, it is also likely to be metabolized by hepatic enzymes and excreted. Therefore, the potential for bioaccumulation is expected to be low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
